Deng CL, Wu B. The potential role of the three-dimensional-bioprinting model in screening and developing drugs . World J Gastroenterol 2022; 28(47): 6788-6790 [PMID: 36620341 DOI: 10.3748/wjg.v28.i47.6788]
Corresponding Author of This Article
Bin Wu, MD, PhD, Chief Doctor, Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 1 Shuaifuyuan Road, Wangfujing, Dongcheng District, Beijing 100730, China. wubin0279@hotmail.com
Research Domain of This Article
Medicine, Legal
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Dec 21, 2022; 28(47): 6788-6790 Published online Dec 21, 2022. doi: 10.3748/wjg.v28.i47.6788
The potential role of the three-dimensional-bioprinting model in screening and developing drugs
Chao-Lin Deng, Bin Wu
Chao-Lin Deng, Bin Wu, Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China
Author contributions: Wu B designed and revised the manuscript; Deng CL wrote the manuscript.
Supported byCAMS Innovation Fund for Medical Sciences, No. 2021-1-I2M-015, and National High Level Hospital Clinical Research Funding, No. 2022-PUMCH-B-003.
Conflict-of-interest statement: All authors declare that they have no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Bin Wu, MD, PhD, Chief Doctor, Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 1 Shuaifuyuan Road, Wangfujing, Dongcheng District, Beijing 100730, China. wubin0279@hotmail.com
Received: October 15, 2022 Peer-review started: October 15, 2022 First decision: October 26, 2022 Revised: October 28, 2022 Accepted: December 5, 2022 Article in press: December 5, 2022 Published online: December 21, 2022
Abstract
Recently, we have read with great interest the original article used different spatial configuration models of colorectal cancer (CRC) for validating the anti-tumor efficacy with Diiminoquinone. We feel obliged to provide new insight into the drug screening models by integrating and analyzing the original method and result. These comments may provide comprehensive insights into three-dimensional drug screening models and the difference between pathologic subtypes in CRC.
Core Tip: Chemotherapy is the main treatment option for inoperable colorectal cancer (CRC). We recently read an article about the anti-cancer effects of Diiminoquinone. We feel obliged to express our opinion on this article on drug screening models and the difference between pathologic subtypes in CRC and hope it could deepen understanding for the reader.
